| 產品名稱 | Triple-Negative Breast Cancer Panel 3 |
|---|---|
| 商品貨號 | B229070 |
| Organism | Homo sapiens, human |
| Components | HCC1599, ATCC CRL-2331
HCC1937, ATCC CRL-2336
HCC1143, ATCC CRL-2321
MDA-MB-468, ATCC HTB-132
HCC38, ATCC CRL-2314
HCC70, ATCC CRL-2315
HCC1806, ATCC CRL-2335
HCC1187, ATCC CRL-2322
DU4475, ATCC HTB-123
BT-549, ATCC HTB-122
Hs 578T, ATCC HTB-126
MDA-MB-231, ATCC HTB-26
MDA-MB-436, ATCC HTB-130
MDA-MB-157, ATCC HTB-24
MDA-MB-453, ATCC HTB-131
BT-20, ATCC HTB-19
HCC1395, ATCC CRL-2324 |
| Applications | Biological understanding of top genetic alterations across tumor types Validation and characterization of potential cancer driver genes Functional profiling and molecular profiling of subtype-specific cancer cell lines Testing small molecules or biologics for cancer drug development |
| Type Strain | no |
| Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Comments | A panel of 17 triple-negative breast tumor cell lines sharing a mesenchymal-like or luminal morphology. See J Clinical Inv (2011) 121(7):2750-2767 for more information.
Ref   Lehmann BD, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121: 2750-2767, 2011. PubMed: 21633166 |
| Product Format | frozen |
| Storage Conditions | LN vapor (less than -130°C) only |
| 梅經理 | 17280875617 | 1438578920 |
| 胡經理 | 13345964880 | 2438244627 |
| 周經理 | 17757487661 | 1296385441 |
| 于經理 | 18067160830 | 2088210172 |
| 沈經理 | 19548299266 | 2662369050 |
| 李經理 | 13626845108 | 972239479 |
